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Thyroid eye disease (TED) is an autoimmune condition in which intense inﬂammation leads to orbital tissue remodeling, includ-
ing the accumulation of extracellular macromolecules and fat. Disease progression depends upon interactions between lympho-
cytes and orbital ﬁbroblasts. These cells engage in a cycle of reciprocal activation which produces the tissue characteristics of TED.
Peroxisome proliferator-activated receptor-γ (PPARγ) may play divergent roles in this process, both attenuating and promoting
disease progression. PPARγ has anti-inﬂammatory activity, suggesting that it could interrupt intercellular communication. How-
ever, PPARγ activation is also critical to adipogenesis, making it a potential culprit in the pathological fat accumulation associated
with TED. This review explores the role of PPARγ in TED, as it pertains to crosstalk between lymphocytes and ﬁbroblasts and the
development of therapeutics targeting cell-cell interactions mediated through this signaling pathway.
Copyright © 2008 G. M. Lehmann et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear hormone receptor superfamily that
bind to DNA as heterodimers formed with retinoid X re-
ceptors (RXRs) [1].These heterodimers control gene expres-
sion by binding to a speciﬁc cis acting DNA element known
as the peroxisome proliferator response element (PPRE)
found in the promoter or enhancer regions of target genes.
PPRE binding can occur in the presence or absence of lig-
and and can either induce or repress gene transcription in a
cell-speciﬁc manner. The ability of PPAR-RXR heterodimers
to transactivate genes results not only from their binding
to DNA, but also from their association with transcrip-
tional coactivators or corepressors. Usually, agonist binding
to these receptors inhibits corepressor and promotes coacti-
vator binding, resulting in increased transcription of target
genes.
Three PPAR subtypes, PPARα (NR1C1), PPARβ/δ
(NUC1, NR1C2), and PPARγ (NR1C3), are encoded by sep-
arate genes [2] .T h r e ei s o f o r m so fP P A R γ,P P A R γ1, PPARγ2,
and PPARγ3 are generated by alternative splicing of the same
mRNA [3]. PPARs are diﬀerentially expressed in a variety
of tissues and are important to the regulation of lipid and
carbohydrate metabolism, energy homeostasis, cellular dif-
ferentiation, apoptosis, and immunity and inﬂammatory re-
sponses [2, 4–6]. The physiological functions of PPARα and
PPARγ have been well characterized, whereas the physio-
logical function of PPARβ/δ is poorly understood although
the protein is widely distributed [3]. PPARα is expressed in
brown adipose tissue, liver, kidney, heart, and skeletal mus-
cle, but is also detected in cells of the vasculature and the2 PPAR Research
immune system [1, 3, 7–10]. Its activation aﬀects transcrip-
tional expression of many genes involved in fatty acid oxi-
dation, lipid metabolism, and inﬂammation [8, 11]. PPARα
agonists (including the ﬁbrates) have been reported to in-
crease levels of high-density lipoproteins (HDL), lower those
of triglycerides and decrease weight gain [12, 13]. They also
induce adipogenesis in ﬁbroblasts in vitro through the in-
duction of genes such as high-mobility group AT-hook 2
(HMGA2) and leptin [8, 14–18].
PPARγ ishighlyexpressedinadiposetissue,colon,retina,
and in cells of the immune system, including platelets [1, 3–
5, 19–25]. The PPARγ1 isoform is the more widely ex-
pressed, while PPARγ2 is mainly found in adipose tissue
and liver [3, 26]. PPARγ3m R N Ai sd e t e c t a b l ei nm o u s e
macrophages, but little is known about the protein expres-
sion and functional signiﬁcance of this isoform [3, 27]. Syn-
thetic PPARγ agonists, including drugs of the thiazolidine-
dione (TZD) family (e.g., ciglitazone, pioglitazone, rosiglita-
zone and troglitazone), have potent insulin-sensitizing prop-
erties [3, 28, 29]. Because of this, rosiglitazone and piogli-
tazone are often prescribed for the treatment of type 2 di-
abetes mellitus [3]. These and naturally occurring PPARγ
ligands, such as lysophosphatidic acid [30], nitrolinoleic
acid [31], prostaglandin D2(PGD2), and 15-deoxy-Δ12,14-
prostaglandin J2(15d-PGJ2)[ 32, 33], are also potent pro-
moters of adipogenesis [3, 28, 34–37]. PGD2 and 15d-PGJ2
are derived from arachidonic acid by the catalytic activi-
ties of the cyclooxygenase-2 (Cox-2) and prostaglandin D
synthase enzymes [28, 32, 33]. PGD2 spontaneously under-
goes a series of dehydration reactions to form the PGJ fam-
ily of prostaglandins, including 15d-PGJ2, and 15d-PGD2,
which can also transactivate PPARγ and induce adipogene-
sis [28, 38–41]. Many of the genes under PPARγ control are
important to glucose uptake, lipid metabolism and storage,
as well as adipogenesis, explaining the ability of PPARγ lig-
ands to increase insulin sensitivity and to trigger the diﬀer-
entiation of ﬁbroblasts to adipocytes [8, 42–44]. Others act
to dampen inﬂammation by decreasing TNFα, IL-6, and IL-
8 production, suggesting potential therapeutic applications
in chronic inﬂammatory diseases [45]. It has been suggested
that the adipogenic action of PPARγ could serve as another
of its anti-inﬂammatory functions because remodeling of in-
ﬂamedtissuetofatmayrenderitmorequiescent[28].Others
would argue that adipogenesis is a proinﬂammatory action
because an increase in fat mass would result in increased re-
lease of proinﬂammatory adipocytokines [36]. In any case,
increased adipogenesis may lead to disease, even if it serves
to attenuate active inﬂammation. Thyroid eye disease (TED)
provides a cogent example of such a circumstance. This re-
view will explore the role that PPARγ and lymphocytes play
inadvancingpathologicaltissueremodelinginTEDandhow
PPARγ maybeexploitedasatargetfortherapeuticstrategies.
2. THYROID EYE DISEASE
TED is a condition in which intense inﬂammation leads to
remodeling and expansion of the connective and adipose
tissues of the orbit, including proliferation and diﬀerenti-
ation of ﬁbroblasts to adipocytes, fat deposition, and dis-
ordered accumulation of extracellular matrix glycosamino-
glycans (GAGs) [8, 46, 47]. Accumulation of GAGs is ac-
companied by dramatic swelling due to their prodigious
water-binding capacity [48, 49]. The increased volume of
orbital connective tissue leads to forward protrusion of the
eye(exophthalmos),accompaniedbynerveandmuscledam-
age [28, 50–56]. In patients with severe TED, the initial in-
ﬂammation subsides, but inﬁltration of muscle ﬁbers by ﬁ-
broblasts leads to ﬁbrosis, potentially limiting their motility
[46,47,50–52].Inadditiontoexophthalmosandextraocular
muscle dysfunction, clinical features of TED include perior-
bital edema, eyelid retraction, dry eye, pain, optic neuropa-
thy, double vision, and vision loss [28, 50, 53, 57].
TED is closely associated with Graves’ disease (GD), a
common autoimmune disorder in which stimulatory au-
toantibodies against the thyroid-stimulating hormone re-
ceptor (TSH-R) cause the thyroid to produce excess thy-
roid hormone [50, 54, 58, 59]. In addition to the hyperme-
tabolic consequences of hyperthyroidism, clinically appar-
ent TED develops in approximately 50–60% of patients with
GD [50, 54–56]. Furthermore, a subset of patients with se-
vere TED develop pretibial dermopathy, a distinctive thick-
ening of the skin, usually occurring on the anterior lower leg
[60, 61]. Although the pathogenesis of the hyperthyroid state
in GD is relatively well understood, many questions remain
regarding the induction and perpetuation of the orbital (and
pretibial) disease that develops in some patients. It is likely
that the hyperthyroid state does not promote connective tis-
sue accumulation within the orbit. Euthyroid GD patients
remain at risk for developing TED [62, 63]. Furthermore,
TED does not usually occur in patients with non-Graves’
hyperthyroidism [64]. It has been suggested that the orbit
is a secondary target of autoimmune attack, involving the
same autoantigen (TSH-R), but resulting in consequences
distinct from those in the thyroid [50, 58, 65]. However,
TSH-R mRNA and protein are expressed widely in many tis-
sues which are unaﬀected in GD, so the basis for the anatom-
ical restriction of TED remains unclear [50, 66]. Moreover,
noconvincingevidencecurrentlyexistsforTSH-Rmediating
any important biological events in orbital connective tissues.
To date, there are no eﬀective means of preventing the
onset of TED or for predicting which GD patients are likely
to exhibit extrathyroidal complications. A study by Khoo et
al. [67] suggested that the presence of thyroid-stimulating
antibodies combined with the absence of antibodies against
thyroid peroxidase is a predictor, but other reports contra-
dict these ﬁndings [68, 69]. Current treatment options for
TED exist, including corticosteroid treatment, external beam
radiation, and surgery, but these interventions are aimed
only at the consequences of the disease, and they fail to pre-
vent or reverse pathological alteration of orbital tissues [70].
Histological examination of orbital tissue in TED suggests
that its development and progression involve interactions
between lymphocytes and ﬁbroblasts [28]. Understanding
these complex interactions may both lead to the identiﬁca-
tion of biomarkers predictive of advanced disease and pro-
vide eﬀective early treatments. It is thought that autoreactive
B lymphocytes initiate the disease state by producing anti-
bodies against self-antigen, such as the TSH-R [58]. Next,G. M. Lehmann et al. 3
in a poorly understood and likely variable event, autoanti-
body production results in orbital ﬁbroblast activation [71].
Activated ﬁbroblasts release chemoattractants that recruit T
lymphocytes and monocytes to the orbit [28, 37, 50, 72–77].
These bone marrow-derived cellscooperate withthe resident
ﬁbroblasts and are engaged in a cycle of reciprocal activation
which ultimately produces the pathological changes in the
orbit characteristic of TED [50].
3. INTERACTIONS BETWEEN LYMPHOCYTES AND
FIBROBLASTS
Orbital tissue from patients with TED is inﬁltrated by T
helper type I (Th1) and T helper type 2 (Th2) lymphocytes,
B lymphocytes, mast cells, and macrophages [47, 50, 59, 78–
82]. It is currently thought that these cells, once recruited
to the orbit, generate cytokines which participate in driv-
ingtissuereactivityandremodeling.Autoimmuneresponses,
like that found with TED, are governed primarily by the
actions of B and T lymphocytes. Lymphocytes are migra-
tory cells that proliferate extensively and develop into acti-
vated eﬀector cells when they encounter speciﬁc antigen in
the proper costimulatory context. Normally, the antigens to
which lymphocytes respond are foreign and several tolerance
mechanisms act to prevent the development of reactivity to
self antigens or autoimmunity [83, 84]; but these tolerance
mechanisms sometimes fail and autoimmunity develops. B
lymphocytes are key to this phenomenon, as activated au-
toreactive B lymphocytes produce autoantibodies and are a
critical source of support for the function of other immune
cells, such as T lymphocytes and ﬁbroblasts [85].
Fibroblasts were once viewed as merely structural by-
standers in the cellular microenvironment, producing ex-
tracellular matrix components, but otherwise uninvolved
in the regulation of tissue homeostasis. Now, it is under-
stood that ﬁbroblasts are a highly interactive cell type, de-
scribed as “sentinel cells,” which are able to detect events
that endanger homeostasis, to communicate these dangers
to cells of the immune system, and to respond directly to
these threats via proliferation and diﬀerentiation to eﬀec-
tor cells that support tissue integrity [58, 66, 72]. Fibrob-
lasts do not merely respond to immune stimulation, but ac-
tively participate in the inﬂammatory pathway through the
synthesis of proinﬂammatory mediators, including IL-1, IL-
6, and IL-8 [28, 73, 74]. They interact with bone marrow-
derived cells in the orbit and are key to the pathophysiol-
ogy of TED [8, 37, 50, 65, 72, 73, 75, 76]. As described ear-
lier, the clinical symptoms of TED result from excess ex-
tracellular macromolecular deposition, ﬁbrosis, and fat ac-
cumulation in the orbit [48, 57]. Several diﬀerences have
been identiﬁed that distinguish orbital ﬁbroblasts harvested
from patients with TED from those derived from normal or-
bital tissues and nonorbital anatomic sites. Orbital ﬁbrob-
lasts from patients with TED synthesize excess GAGs, in-
cluding hyaluronan, are unusually proliferative and can dif-
ferentiate into adipocytes, leading to accumulation of fat
[50, 86, 87]. In addition, they do not express IL-1 recep-
tor antagonist at levels found in other ﬁbroblasts. This re-
sults in excessively high levels of Cox-2 and PGE2 in response
to proinﬂammatory cytokines [47, 50, 59, 77, 86, 88–91].
They also display lymphocyte costimulatory molecules such
as CD40 [59, 77, 86, 88]. These characteristics suggest that
theﬁbroblastphenotypeunderliestheselectiveanatomicdis-
tributionofTED-associatedinﬂammationandtissueremod-
eling [37, 47, 50, 59, 73, 75, 92, 93].
The unique features of orbital ﬁbroblasts provide an en-
vironment in which TED might develop, but the disease is
characterized also by mononuclear cell inﬁltration [48, 59,
94]. Substantial data support the concept that inﬁltrating T
lymphocytes interact with ﬁbroblasts, activate them, and re-
sult in their proliferation, synthesis of extracellular macro-
molecules, and diﬀerentiation to adipocytes [50, 59]. A sum-
mary of this model for the pathogenesis of TED is depicted
in Figure 1. It is thought that autoantigen expression by or-
bital ﬁbroblasts instigates T lymphocyte recruitment to the
orbit [48, 95, 96]. The autoantigen may be TSH-R or an-
other protein, such as insulin-like growth factor-1 recep-
tor (IGF-1R) [34, 48, 54, 94–98]. Recruited T lymphocytes
stimulate orbital tissue remodeling by initiating ﬁbroblast
proliferation and hyaluronan synthesis [50]. They also con-
tribute to the perpetuation of the inﬂammatory response
by (1) stimulating ﬁbroblast production of chemokines, like
IL-16 and RANTES, and cytokines, like IL-6, that initi-
ate T and B lymphocyte migration to local environments,
and (2) increasing ﬁbroblast presentation of autoantigens
[50, 73, 74, 76, 77, 99]. The T lymphocyte-ﬁbroblast interac-
tionoccursviacostimulatorymolecules,adhesionmolecules,
and cytokines like IFNγ,I L - 1 β,a n dT N F α [50, 99]. One
mechanism by which T lymphocytes may communicate with
orbitalﬁbroblastsisthroughtheCD40-CD40ligandpathway
[50,74,88].CD40isacellsurfacereceptorfoundonantigen-
presenting cells, whereas CD40 ligand (CD40L, CD154) is
expressed on T lymphocytes [50]. Ligation of CD40 on B
lymphocytes or other antigen-presenting cells is necessary
for eﬃcient activation of T-lymphocyte eﬀector functions
[100, 101]. Recently, it has been shown that orbital ﬁbrob-
lasts from TED patients express high levels of CD40, which
is upregulated in the presence of IFNγ, produced by inﬁltrat-
i n gTl y m p h o c y t e s[ 74, 76, 77, 99]. Activation by CD40L in-
duces hyaluronan synthesis, IL-6 and IL-8, Cox-2 and PGE2
[50, 74, 86, 102]. Thus, the CD40-CD40L bridge is one po-
tential pathway through which T lymphocytes could inﬂu-
ence ﬁbroblast activation and proliferation in TED [50].
Fibroblasts respond to T lymphocyte-mediated activa-
tion by releasing factors that recruit, activate, and promote
the proliferation of T lymphocytes, thus participating in
the perpetuation of inﬂammation [35, 50, 103]. In patients
with clinically signiﬁcant TED, even in those whose hyper-
thyroidism is well controlled, B and T lymphocytes have
been shown to display a distinctly activated phenotype dif-
ferent from those derived from control donors [59]. This
sustained activation following treatment of hyperthyroidism
contributes to orbital inﬂammation and tissue remodeling
observed in late-stage TED. A recent study found that orbital
ﬁbroblastsfromTEDpatientsmaymodulatetheactivityofT
lymphocytes through the production of CXCL10 [35]. TED
patients with active disease had higher serum CXCL10 levels
than patients with inactive disease. CXCL10 release enhances4 PPAR Research
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Figure 1: According to one current model, TED is triggered by binding and activation of orbital ﬁbroblasts by autoantibodies. These au-
toantibodies could be speciﬁc for antigens such as TSH-R and/or IGF-1R. Activated orbital ﬁbroblasts release chemokines, including IL-16,
RANTES, and CXCL10, which recruit T lymphocytes into the orbit. These lymphocytes then interact with ﬁbroblasts, potentially activating
each other, further promoting cytokine production (IFNγ,T N F α,P G D 2, and 15d-PGJ2) and secretion of T cell-activating factors by the
ﬁbroblasts (IL-8 and CXCL10). Fibroblasts are also stimulated to secrete IL-6 (promoting B cell diﬀerentiation) and to increase autoantigen
presentation, both of which amplify the overall response. The interactions of ﬁbroblasts with T cells result in the deposition of extracellular
matrix molecules, ﬁbroblast proliferation, and fat accumulation.
the migration of T lymphocytes into the orbit, where they
secrete IFNγ and TNFα.I F N γ levels were higher in TED pa-
tients than in patients with GD without orbital involvement.
IFNγ and TNFα synergistically induced CXCL10 release by
orbital ﬁbroblasts, thereby perpetuating a positive feedback
loop [35, 50, 103]. PPARγ activation was found to play an
inhibitory role in this process, both in vivo and in vitro [35].
4. PPARγ LIGANDS AND INFLAMMATION
PPARγ ligands attenuate activity of inﬂammatory bowel dis-
ease in animal models [35, 104–106], experimental autoim-
mune encephalomyelitis [107, 108], arthritis [21], and pso-
riasis [109]. Clinical trials have shown that they amelio-
rate inﬂammation in patients with mild-to-moderate cases
of ulcerative colitis [1, 110, 111]. At least some of the anti-
inﬂammatory eﬀects of PPARγ ligands result from direct ac-
tions on cells of the innate and adaptive immune system
[23, 112–114]. In macrophages, they inhibit activation and
production of inﬂammatory cytokines such as TNFα,I L -
1β, and IL-6 [25, 115, 116]. In addition, PPARγ activation
has been shown to skew macrophage diﬀerentiation into a
more anti-inﬂammatory phenotype [117]. In dendritic cells,
PPARγ agonists downregulate the synthesis of chemokines
involved in the recruitment of T lymphocytes [35, 118].
Evidence for a physiological role of PPARγ in regulat-
ing B lymphocyte function was generated in studies using
PPARγ-haploinsuﬃcient mice [21]. B lymphocytes derived
from these mice exhibit increased proliferation and survival,
enhanced antigen speciﬁc immune response, and sponta-
neous NF-κBa c t i v a t i o n[ 1, 21]. Our laboratory has shown
that normal and malignant mouse and human B lympho-
cytes express PPARγ and that exposure to certain PPARγ
ligands inhibits their proliferation and can induce apopto-
sis [24, 113, 119]. Several anti-inﬂammatory mechanisms
of PPARγ have been suggested, including inhibition of NF-
κB, AP1 and STAT transcription factors [120, 121]. A recent
study demonstrated that some of these eﬀects are PPARγ-
independent [122]. PPARγ also regulates inﬂammation by
blocking gene transcription through “transrepression.” Sev-
eral models of transrepression by PPARγ have been pro-
posed. In one of them, PPARγ-RXR complexes are thought
tosequestercoactivators,therebydownregulatingothertran-
scription factors. A second model suggests that interactions
between transcription factors result in mutual antagonism
of gene activation [123]. A recent report by Pascual et al.G. M. Lehmann et al. 5
demonstrated a PPARγ ligand-dependent sumoylation of
PPARγ that leads to its recruitment to repressor complexes
in the promoter regions of inﬂammatory genes regulated by
NF-κB. This prevents their release and suppresses proinﬂam-
matory gene expression [124].
PPARγ also plays a role in T lymphocyte regulation,
and its level is upregulated following activation [5, 125].
PPARγ ligands inhibit T lymphocyte proliferation and re-
duce the production of IFNγ,T N F α, and IL-2 [23, 126, 127].
These inhibitory eﬀects result from the direct interaction
between PPARγ and the transcription factor nuclear factor
of activated T cells (NFAT) [128]. Recent observations re-
ported by Wohlfert et al. could illuminate yet another mech-
anism through which PPARγ controls immune responses
[129]. They investigated the connection between PPARγ and
CD4+ CD25+ regulatory T lymphocytes (Tregs). Tregs have
been demonstrated to play a key role in regulating autoim-
munity and immune responses [130–132]. There are two
diﬀerent subtypes of Tregs: thymus-derived natural Tregs
(nTregs) and inducible or adaptive Tregs (iTregs). nTregs are
always present in normal individuals as a functionally ma-
ture population constitutively expressing CD25, while iTregs
are CD4+ CD25+ Tl y m p h o c y t e sw h i c hd i ﬀerentiate from
CD4+ CD25− eﬀector T lymphocytes in the periphery un-
der a speciﬁc cytokine stimulation [133, 134]. Wohlfert et al.
showed that ciglitazone enhanced the conversion of eﬀector
T lymphocytes into iTregs. Moreover, PPARγ expression in
nTregs was required for the in vivo eﬀectsofligandtreatment
in a murine model of graft-versus-host disease. These ﬁnd-
ings suggest that PPARγ ligands may enhance the activity of
regulatory T lymphocytes while dampening the activation of
other T lymphocyte subsets. The anti-inﬂammatory poten-
tial of PPARγ may be relevant to TED because this transcrip-
tion factor is present in orbital tissues from TED patients, its
activity may be involved in the regulation of IFNγ-induced
chemokine expression, and its activators might attenuate the
recruitment of activated T lymphocytes to sites of inﬂam-
mation [35, 106, 118, 135, 136]. Together, the evidence in-
dicates that PPARγ ligands could interrupt communication
between mononuclear cells and ﬁbroblasts [1, 35, 50]. How-
ever, PPARγ ligands may also promote T lymphocyte syn-
thesis of IL-8 [137, 138]. Thus, the eﬀects of PPARγ on T
lymphocytes are complex and require further study.
End-stage TED can culminate with permanent patho-
logical changes including the diﬀerentiation of ﬁbroblasts to
adipocytes that contribute to increased connective tissue vol-
ume [28]. Adipogenesis is regulated by the interplay of sev-
eral factors, including PPARα and γ [8, 28, 42, 139]. Natu-
ral and synthetic activators of PPARγ are known to stimu-
late lipid accumulation and the expression and secretion of
adiponectin [28, 34, 139, 140]. PPARγ antagonists prevent
triglyceride accumulation in orbital ﬁbroblasts exposed to
PPARγ agonists. This supports the concept that PPARγ ex-
pression and activation are crucial for adipocytic diﬀerenti-
ation [28, 35, 36]. PPARγ levels are higher in orbital tissue
frompatientswithactiveTEDthanincontrolsorindividuals
with inactive TED [35, 135]. Responses of orbital ﬁbroblasts
to PPARγ ligands provide an interesting link to T lympho-
cyte activity. T lymphocytes from patients with GD express
constitutively high levels of Cox-2, and produce substantial
PGD2 and 15d-PGJ2 [28, 141]. We have developed the model
depicted in Figure 2, in which T lymphocyte inﬁltration of
the orbit results in adipocytic diﬀerentiation of ﬁbroblasts
[28, 142]. In fact, coculture of orbital ﬁbroblasts from TED
patients with activated T lymphocytes results in cytoplasmic
accumulation of lipid droplets in ﬁbroblasts [28].
5. PPARγ AND TISSUE REMODELING
Adipogenesis has been suggested to be a mechanism for
stanching chronic inﬂammation [28]. Alternatively, this
process may promote further inﬂammation by increasing
proinﬂammatory adipocytokine production [36]. Orbital
adipocytes express immunoreactive and functional TSH-R
[8, 34, 54, 87, 95, 97, 98]. Positive correlation between TSH-
R, PPARγ, and other adipocytic diﬀerentiation markers has
been observed in tissues from TED patients [34]. Upregula-
tion of an autoantigen on the surface of orbital ﬁbroblasts
could enhance the recruitment of autoreactive T lympho-
cytes to the orbit, fueling inﬂammation [36, 55]. Whether
adipogenesis serves to abateor amplifyinﬂammation, theas-
sociated increase in orbital tissue mass is undesirable. Thus,
despite anti-inﬂammatory actions of PPARγ, its proadi-
pogenicfunctionsintheorbitmightworsenthedisease,con-
traindicatingtheuseofagentsactivatingthispathwayinTED
[36]. Several case reports have described development of ex-
ophthalmos in patients receiving TZD treatment for type 2
diabetes [28, 36, 143]. In particular, a patient with stable and
inactive TED experienced aggravated disease with orbital fat
expansion following pioglitazone therapy [28, 35, 36].
6. PPARγ AS A THERAPEUTIC TARGET
PPARγ modulators with selective activities would be re-
quired if PPARγ function is to be targeted as a TED ther-
apeutic. Identiﬁcation of selective PPARγ modulators, or
SPPARγMs, has been sought as a better therapy for type 2
diabetes [3, 144]. In this context, designing partial PPARγ
agonists that display insulin-sensitizing activity but lack adi-
pogenic properties might be attractive [3, 144, 145]. The
SPPARγMs take advantage of both the large ligand-binding
domain of PPARγ and the complex interactions between
PPARγ and its coactivators and corepressors [1, 3, 144,
146]. The ligand binding domain mediates interactions with
transcriptional coactivator or corepressor proteins through
ligand-dependent conformational changes in the C-terminal
activation function 2 (AF2) α-helix [1, 144, 146]. In the ab-
sence of ligand, PPARγ f u n c t i o n sa sa na c t i v et r a n s c r i p t i o n a l
repressor by binding both target genes and transcriptional
corepressors [1]. Binding of classical ligands causes the AF2
α-helix to move in such a way that a high-aﬃnity bind-
ing site for nuclear receptor coactivator proteins is created
while corepressor proteins are dislodged from their binding
sites [1, 144, 146–149]. Therefore, the structural change in









Figure 2: T lymphocytes in TED patients express constitutively elevated levels of Cox-2, one enzyme critical to the production of the
naturally-occurring PPARγ ligand 15d-PGJ2. When these lymphocytes inﬁltrate the orbit, 15d-PGJ2 is secreted in resident ﬁbroblasts result
in their diﬀerentiation into adipocytes.
[1]. Because the position of the AF2 domain relative to the
ligand binding domain determines whether coactivators or
corepressors are recruited, ligands that ﬁt into the binding
domain without directly interacting with the AF2 helix, such
as SPPARγM s ,c a na c ta sa g o n i s t sf o rs o m er e c e p t o rf u n c -
tions and as antagonists for others [1, 3, 144, 145, 150–153].
Although not yet clinically available, several SPPARγMs
have shown promise as potential glucose-lowering agents in
type 2 diabetes. For example, metaglidasen has been shown
in vitro to act as a partial PPARγ agonist/antagonist, with
only a weak ability to recruit coactivators, such as CBP,
DRIP205/TRAP220, and p300 [144]. Compared to rosigli-
tazone, metaglidasen is less adipogenic in primary human
adipocytes and mouse 3T3-L1 adipocytes. In rodent mod-
els of insulin resistance, both metaglidasen and another
SPPARγM, PAT5A, increased insulin sensitivity to levels
comparable to those seen with rosiglitazone, with only weak
adipogenic potential [3, 144, 154]. Consistent with the pre-
clinical ﬁndings, metaglidasen appears to have comparable
eﬃcacy to pioglitazone and rosiglitazone in type 2 diabetics,
withouttheundesirablesideeﬀectofweightgain[144].Since
developing SPPARγMs to target insulin resistance seems
achievable, it is anticipated that the anti-inﬂammatory prop-
erties of PPARγ will be targeted in the future [3].
7. FUTURE PROSPECTS
PPARγ may play an important role in the development of
TED. Studies have taken advantage of the availability of or-
bital tissue from TED patients. Orbital tissues from patients
with GD but without TED are far less available. Potential dif-
ferences between orbital tissues from “normal” and TED pa-
tients have not been fully explored. Similarly, few compar-
isons between tissues from early and late stage TED patients
have been possible. Thus, an animal model of TED with ﬁ-
delity to human disease is critical.
T lymphocytes and ﬁbroblasts exist as multiple phe-
notypic subsets in the orbit. Aniszewski et al. [82]f o u n d
that the phenotypes of orbital T lymphocytes in TED pa-
tients changed with disease duration. From that report, the T
helper lymphocyte Th1subset may predominate early, while
Th2 lymphocytes may become more abundant later. Fur-
thermore, as discussed previously, the role of Tregs in TED
may diﬀer from that of Th1 and Th2 lymphocytes. Studies
comparing PPARγ expression and function in each of these
subpopulations may lead to better understanding of the role
that this transcription factor plays in TED.
Like T lymphocytes, orbital ﬁbroblasts exist in multi-
ple subpopulations. Two major subsets of orbital ﬁbrob-
last are deﬁned based on their expression of a surface pro-
tein known as Thy-1 (CD90) whose function is unknown
[37, 73, 155, 156]. The balance between Thy-1 negative and
Thy-1 positive populations in the orbit may prove important
to normal regulation of inﬂammation because these subsets
exhibit distinct biosynthetic capabilities [73]. However, this
balance may also be critical to the development and progres-
sion of TED. Depending on the signaling environment and
their phenotype, ﬁbroblasts can be stimulated to diﬀerenti-
ate into myoﬁbroblasts or lipoﬁbroblasts [37, 157]. Myoﬁ-
broblasts are important in wound healing, but they may also
contribute to ﬁbrosis in late-stage TED patients [158]. The
presence of lipoﬁbroblasts is an indication of pathology; in
TED, their presence may result in excess orbital fat deposi-
tion [28]. Data suggest that the potential for terminal diﬀer-
entiation depends on Thy-1 display. TGF-β triggers diﬀeren-
tiation of Thy-1+ ﬁbroblasts into myoﬁbroblasts, identiﬁed
by their expression of α-SMA [157]. Adipocytic diﬀerentia-
tionoccursintheThy-1− subset[37,157].PPARγ expression
or function may diﬀer between Thy-1+ and Thy-1− subsets,
explaining their divergent potential for diﬀerentiation.
Finally, TED is one of several pathological conditions
in which chronic inﬂammation leads to tissue remodeling
and inappropriate fat deposition. Sj¨ ogren syndrome, inﬂam-
matory bowel disease, nonalcoholic fatty liver disease, and
atherosclerosis are examples [159–162]. PPARγ has been
shown to play a major role in the regulation of atherogenesis
by countering the inﬂammation-provoking action of platelet
adhesion and activation [3]. Because PPARγ has been impli-
cated in these diseases, it may prove an important determi-
nant in diseases such as TED.
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